Consequently SNRPD3, MYCN, and PRMT5 expression levels may be used as predictive biomarkers for PRMT5 inhibitor response, not only in neuroblastoma, but potentially other cancers. This evidence concerns the gene SNRPD3 and neuroblastoma.